Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306

Research output: Contribution to journalArticle

Original languageEnglish
Article numbermds332
Pages (from-to)2771-2772
Number of pages2
JournalAnnals of Oncology
Volume23
Issue number10
DOIs
Publication statusPublished - Oct 2012

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

@article{abe5bba2709d4c2e8993d7ed6f453511,
title = "Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306",
author = "F. Pietrantonio and Garassino, {M. C.} and V. Torri and {De Braud}, F.",
year = "2012",
month = "10",
doi = "10.1093/annonc/mds332",
language = "English",
volume = "23",
pages = "2771--2772",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "10",

}

TY - JOUR

T1 - Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306

AU - Pietrantonio, F.

AU - Garassino, M. C.

AU - Torri, V.

AU - De Braud, F.

PY - 2012/10

Y1 - 2012/10

UR - http://www.scopus.com/inward/record.url?scp=84867127538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867127538&partnerID=8YFLogxK

U2 - 10.1093/annonc/mds332

DO - 10.1093/annonc/mds332

M3 - Article

C2 - 22875835

AN - SCOPUS:84867127538

VL - 23

SP - 2771

EP - 2772

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 10

M1 - mds332

ER -